Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

213 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Myosin Inhibition and Left Ventricular Diastolic Function in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Insights From the VALOR-HCM Study.
Cremer PC, Geske JB, Owens A, Jaber WA, Harb SC, Saberi S, Wang A, Sherrid M, Naidu SS, Schaff H, Smedira NG, Wang Q, Wolski K, Lampl KL, Sehnert AJ, Nissen SE, Desai MY. Cremer PC, et al. Among authors: naidu ss. Circ Cardiovasc Imaging. 2022 Dec;15(12):e014986. doi: 10.1161/CIRCIMAGING.122.014986. Epub 2022 Nov 6. Circ Cardiovasc Imaging. 2022. PMID: 36335645 Clinical Trial.
Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 56 Results From the VALOR-HCM Randomized Clinical Trial.
Desai MY, Owens A, Wolski K, Geske JB, Saberi S, Wang A, Sherrid M, Cremer PC, Lakdawala NK, Tower-Rader A, Fermin D, Naidu SS, Smedira NG, Schaff H, McErlean E, Sewell C, Mudarris L, Gong Z, Lampl K, Sehnert AJ, Nissen SE. Desai MY, et al. Among authors: naidu ss. JAMA Cardiol. 2023 Oct 1;8(10):968-977. doi: 10.1001/jamacardio.2023.3342. JAMA Cardiol. 2023. PMID: 37639243 Free PMC article. Clinical Trial.
Mavacamten in Obstructive Hypertrophic Cardiomyopathy Patients Referred for Septal Reduction: Health Status Analysis Through Week 56 in VALOR-HCM Trial.
Desai MY, Owens A, Wolski K, Geske JB, Saberi S, Wang A, Sherrid M, Cremer PC, Lakdawala NK, Tower-Rader A, Fermin D, Naidu SS, Smedira NG, Schaff H, McErlean E, Sewell C, Zhong Y, Wyrwich KW, Lampl KL, Sehnert AJ, Nissen SE, Spertus JA; VALOR-HCM Investigators. Desai MY, et al. Among authors: naidu ss. J Am Coll Cardiol. 2024 Sep 10;84(11):1041-1045. doi: 10.1016/j.jacc.2024.06.025. J Am Coll Cardiol. 2024. PMID: 39232631 Free article. Clinical Trial. No abstract available.
Mavacamten-Associated Temporal Changes in Left Atrial Function in Obstructive HCM: Insights From the VALOR-HCM Trial.
Desai MY, Okushi Y, Wolski K, Geske JB, Owens A, Saberi S, Wang A, Cremer PC, Sherrid M, Lakdawala NK, Tower-Rader A, Fermin D, Naidu SS, Lampl KL, Sehnert AJ, Nissen SE, Popovic ZB; VALOR-HCM Investigators. Desai MY, et al. Among authors: naidu ss. JACC Cardiovasc Imaging. 2025 Mar;18(3):251-262. doi: 10.1016/j.jcmg.2024.08.005. Epub 2024 Sep 2. JACC Cardiovasc Imaging. 2025. PMID: 39254622 Free article. Clinical Trial.
Limited Concordance of Left Ventricular Ejection Fraction and Chamber Dimensions With Automated Assessments in Hypertrophic Cardiomyopathy: A Substudy From VALOR-HCM.
Parizher G, Haouzi A, Jaber WA, Owens A, Wolski K, Geske JB, Saberi S, Wang A, Sherrid M, Lakdawala NK, Tower-Rader A, Fermin D, Naidu SS, Popovic ZB, Smedira NG, Schaff H, McErlean E, Sewell C, Lampl K, Sehnert AJ, Nissen SE, Desai MY, Cremer PC. Parizher G, et al. Among authors: naidu ss. J Am Soc Echocardiogr. 2025 Apr;38(4):356-358. doi: 10.1016/j.echo.2024.12.009. Epub 2024 Dec 28. J Am Soc Echocardiogr. 2025. PMID: 39733991 No abstract available.
Long-Term Response of Obstructive Hypertrophic Cardiomyopathy Patients to Mavacamten Based on Sex: Insights From the VALOR-HCM Trial.
Desai MY, Saberi S, Geske JB, Wang A, Cremer P, Fermin DR, Zenker MA, Lakdawala NK, Tower-Rader A, Naidu SS, Lampl K, Owens A; VALOR-HCM Investigators. Desai MY, et al. Among authors: naidu ss. JACC Heart Fail. 2025 Jun;13(6):1037-1040. doi: 10.1016/j.jchf.2025.02.005. Epub 2025 Mar 17. JACC Heart Fail. 2025. PMID: 40100181 Free article. No abstract available.
Long-Term Favorable Cardiac Remodeling in Obstructive Hypertrophic Cardiomyopathy Patients Treated With Mavacamten for Up to 128 Weeks: Insights From the VALOR-HCM Trial.
Desai MY, Okushi Y, Wolski K, Geske JB, Owens AT, Wang Q, Saberi S, Wang A, Cremer P, Lakdawala NK, Sherrid MV, Tower-Rader A, Fermin DR, Zenker MA, Naidu SS, Lampl K, Nissen SE, Popovic Z; VALOR-HCM investigators. Desai MY, et al. Among authors: naidu ss. JACC Cardiovasc Imaging. 2025 Dec;18(12):1300-1311. doi: 10.1016/j.jcmg.2025.07.019. Epub 2025 Sep 16. JACC Cardiovasc Imaging. 2025. PMID: 40956275 Clinical Trial.
213 results